Africa Races to Make Its Own Vaccines

SOUTH AFRICA · SCIENCE

Africa is racing to make its own vaccines, so it never again waits at the back of the global queue as it did during the pandemic. From South Africa’s first homegrown HIV trial to new factories, the African vaccine push is gathering real pace in 2026.

Why Africa wants to make its own vaccines

The pandemic taught a bitter lesson. As rich countries hoarded doses, Africa waited at the back of the queue, importing almost all of the vaccines it eventually received.

Leaders across the continent came away determined never to be so exposed again. Making vaccines locally is now framed as a matter of health security, not just industrial policy.

The goal is simple: a continent that can protect itself without waiting for anyone else.

South Africa leads the science

South Africa has emerged as the continent’s scientific engine. Researchers there have launched the country’s first in-human HIV vaccine trial, a marker of how far local capacity has come.

The country also hosts a hub set up to spread messenger-RNA vaccine technology to developing nations. That positions it not merely as a test site but as a source of know-how.

What was once research done for others is increasingly research done by Africans.

Building the factories

Science means little without the means to manufacture at scale. Biovac, a South African producer, is building one of the continent’s first end-to-end vaccine plants, financed by a group of global development lenders.

Several other manufacturers are constructing facilities, with technology transfers underway to give them the recipes and the rights. The aim is to turn imported vials into locally made ones.

Factories, in this story, matter as much as laboratories.

The financing is designed to share the early risk that has scared off private investors before. The bet is that patient capital now will build an industry that pays off later.

A continental effort

The push is being coordinated, not left to chance. The Africa Centres for Disease Control and Prevention is driving the first continent-wide immunisation plan and pressing for far more local production.

The African Union has set a target for the continent to make most of its own vaccines within a generation. Pooled buying power is meant to give new factories the demand they need to survive.

It is an attempt to build an industry, not just a few plants.

Fresh momentum in 2026

The effort gained pace this year. In early June a global coalition pledged $62 million to fast-track three vaccine candidates against a dangerous, Ebola-like virus, with African trials central to the plan.

The Africa CDC has promised a homegrown vaccine and treatment for the disease by the end of the year. Officials also expect around eleven African-made vaccines, covering eight diseases, to reach the market within five years.

Momentum, for once, is on the continent’s side.

Each new commitment makes the next one easier to secure. Donors and African governments are, for the moment, pulling in the same direction.

The hard road to market

The obstacles are real. New factories need steady financing, harmonised regulation through a young African Medicines Agency, and guaranteed demand to compete with cheap imports.

Without those, even well-built plants can sit idle, as some have before. Sustaining an industry is harder than launching one.

The challenge now is to keep the momentum from fading once the headlines move on.

Why it matters

Vaccine self-reliance is about more than medicine. It means health security, skilled jobs, scientific prestige and a measure of soft power for a continent long treated as a recipient.

It also matters to the world, since a continent that can make and test vaccines strengthens global defences against the next pandemic. Africa is no longer content to be only a market or a study site.

The ambition is nothing less than to make its own future.

Frequently asked questions